How we manage autologous stem cell transplantation for patients with multiple myeloma

The lymphoma-like polychemotherapy regimen “Dexa-BEAM” in advanced and extramedullary multiple myeloma

(2014) Leo Rasche et al.   ANNALS OF HEMATOLOGY

International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

(2014) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Autologus Stem Cell Transplatation as a Care Option in Elderly Patients. A Review

(2013) Lucia Fratino et al.   Anti-Cancer Agents in Medicinal Chemistry

Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma

(2013) Luciano J. Costa et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age

(2013) Philip L. McCarthy et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification

(2013) Luciano J. Costa et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results

(2013) F. Gay et al.   BLOOD

Time-dependent endpoints as predictors of overall survival in multiple myeloma

(2013) Jorge Félix et al.   BMC CANCER

Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy

(2013) S K Kumar et al.   BONE MARROW TRANSPLANTATION

Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center

(2013) M Pozotrigo et al.   BONE MARROW TRANSPLANTATION

Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-SCT

(2013) S V Glavey et al.   BONE MARROW TRANSPLANTATION

Second autologous transplant as salvage therapy in multiple myeloma

(2013) Djordje Atanackovic et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors

(2013) Ivo Abraham et al.   Expert Opinion On Drug Safety

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

(2013) C. Scheid et al.   HAEMATOLOGICA

Autologous transplant in multiple myeloma with an augmented conditioning protocol

(2013) Badran Abu Zaid et al.   LEUKEMIA & LYMPHOMA

Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma

(2013) D. Reece et al.   ONCOLOGIST

The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: A single center experience from Turkey

(2013) Serdar Sivgin et al.   TRANSFUSION AND APHERESIS SCIENCE

Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

(2012) Margarita Blanes et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

(2012) P. L. Bergsagel et al.   BLOOD

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

(2012) L. Rosinol et al.   BLOOD

Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure

(2012) L J Costa et al.   BONE MARROW TRANSPLANTATION

Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT

(2012) H-Y Yhim et al.   BONE MARROW TRANSPLANTATION

Second auto-SCT for treatment of relapsed multiple myeloma

(2012) W I Gonsalves et al.   BONE MARROW TRANSPLANTATION

Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells

(2012) K E Herbert et al.   BONE MARROW TRANSPLANTATION

Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation

(2012) Jonathan S. Bleeker et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma

(2012) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

(2012) S Z Usmani et al.   LEUKEMIA

Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma

(2012) Neil C. Dunavin et al.   LEUKEMIA & LYMPHOMA

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of Blood and Marrow Transplantation Registry

(2011) Gordon Cook et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

(2011) A. Palumbo et al.   BLOOD

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

(2011) K. Neben et al.   BLOOD

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

(2011) M. Cavo et al.   BLOOD

Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma

(2011) A I Chen et al.   BONE MARROW TRANSPLANTATION

Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma

(2011) Shaji K. Kumar et al.   CANCER

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

(2011) G. J. Morgan et al.   HAEMATOLOGICA

Stem cell transplant: an effective salvage therapy for multiple myeloma

(2011) Morie A. Gertz   LEUKEMIA & LYMPHOMA

Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction

(2010) M. A. Gertz et al.   BLOOD

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

(2010) B. Nair et al.   BLOOD

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma

(2010) M A Gertz et al.   BONE MARROW TRANSPLANTATION

A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study

(2010) S. Lonial et al.   CLINICAL CANCER RESEARCH

Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma

(2010) Mervi Putkonen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma

(2010) W J Chng et al.   LEUKEMIA

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)

(2009) M. Roussel et al.   BLOOD

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

(2009) A. Hoering et al.   BLOOD

Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis

(2009) A. Kumar et al.   JNCI-Journal of the National Cancer Institute

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative

(2009) Morie A. Gertz et al.   MAYO CLINIC PROCEEDINGS

Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis

(2008) Shaji K. Kumar et al.   AMERICAN JOURNAL OF HEMATOLOGY

Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma

(2008) M A Gertz et al.   BONE MARROW TRANSPLANTATION

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

(2008) Ruben Niesvizky et al.   BRITISH JOURNAL OF HAEMATOLOGY

The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma

(2008) Mustaqeem Siddiqui et al.   LEUKEMIA & LYMPHOMA

Management strategies for poor peripheral blood stem cell mobilization

(2008) Rainer Moog   TRANSFUSION AND APHERESIS SCIENCE